Cytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024. In the quarter to June 2026, revenue fell 57.1%, EPS fell 33.9%, free cash flow fell 24.0% and total debt rose 57.7%, each against the same quarter a year earlier.
Follow CYTK
Cytokinetics, Incorporated (CYTK) EV/Sales
As of 16 October 2026, Cytokinetics, Incorporated (CYTK) trades at a EV/Sales of 121×. Over the past ten years it has ranged from 2.4× (November 2017) to 2,039× (April 2024); the current reading is higher than 79% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 89.8× | (65.78%) |
| FY2024 | 262× | (75.67%) |
| FY2023 | 1,079× | 2,576.66% |
| FY2022 | 40.3× | (11.05%) |
| FY2021 | 45.3× | 149.12% |
| FY2020 | 18.2× | (5.97%) |
| FY2019 | 19.3× | 224.72% |
| FY2018 | 6.0× | (61.16%) |
| FY2017 | 15.3× | 342.30% |
| FY2016 | 3.5× | (67.86%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 166× | 107.42% |
| Mar 2026 | 80.0× | (10.88%) |
| Dec 2025 | 89.8× | 16.58% |
| Sep 2025 | 77.0× | 73.06% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ABVX Abivax SA Sponsored ADR compare | n/m |
| CAI Caris Life Sciences,�Inc. compare | 8.3× |
| TGTX TG Therapeutics, Inc. compare | 9.8× |
| AXSM Axsome Therapeutics, Inc. compare | 10.2× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 10.9× |
| KRYS Krystal Biotech, Inc. compare | 19.3× |
| PTGX Protagonist Therapeutics, Inc. compare | 27.4× |
| KYMR Kymera Therapeutics, Inc. compare | 91.4× |
| CYTK Cytokinetics, Incorporated | 121× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)